Glioblastoma Multiform (GBM) is the most common and most aggressive malignant primary brain tumor. The GBM solid tumor is relatively diffused, showing extremely aggressive proliferation from a core to other brain tissues. In Silenseed, we are developing a new generation LODER delivery platform (“LODER-nano”) optimized to the specific physiology of this type of brain tumor. Silenseed is exploring the potential of using RNAi-based therapeutics combined with the LODER-nano to yield the optimal combination of high efficacy and low toxicity. Several prospective targets for our RNAi-based drugs currently are in pre-clinical evaluation.